This Is What Whales Are Betting On DexCom | Nasdaq

Oct 7, 2024 · Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM) ... This Is What Whales Are Betting On DexCom October 07, 2024 — 12:46 pm EDT.

CouponFollow Extension

6%
OFF

CIBC Asset Management Inc Increases Stock Position In DexCom, …

1 week from now

15 hours ago · CIBC Asset Management Inc raised its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.6% in the 3rd quarter, according to its most recent 13F …

marketbeat.com

9%
OFF

Los Angeles Capital Management LLC Has $451,000 Stock

1 week from now

7 hours ago · Los Angeles Capital Management LLC trimmed its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 80.9% in the third quarter, according to its most recent …

marketbeat.com

60%
OFF

Up 60%, Why I Believe DexCom Is One Of The Best Healthcare …

1 week from now

Dec 11, 2023 · One of the companies I started covering this year is DexCom, Inc. (NASDAQ:DXCM), the medical devices giant from San Diego, California. My first article was …

seekingalpha.com

$60
OFF

This Is What Whales Are Betting On PayPal Holdings | Nasdaq

1 week from now

Nov 6, 2024 · Predicted Price Range Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $95.0 for PayPal Holdings …

nasdaq.com

$39
OFF

This Is What Whales Are Betting On ARM Holdings - Benzinga

1 week from now

6 days ago · Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume; ARM: PUT: TRADE: BEARISH: 01/16/26: $39.8: $39.55: …

benzinga.com

$150
OFF

This Is What Whales Are Betting On Applied Mat - Benzinga

1 week from now

5 days ago · Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Applied Mat's whale trades within a strike price range from $150.0 …

benzinga.com

96%
OFF

This Is What Whales Are Betting On Moderna | Nasdaq

1 week from now

Oct 9, 2024 · Current Position of Moderna Currently trading with a volume of 1,302,422, the MRNA's price is up by 0.96%, now at $58.95. RSI readings suggest the stock is currently may …

nasdaq.com

42%
OFF

This Is What Whales Are Betting On Trump Media & Technology

1 week from now

3 days ago · The general mood among these heavyweight investors is divided, with 42% leaning bullish and 47% bearish. Among these notable options, 10 are puts, totaling $744,800, and 9 …

nasdaq.com

FAQs about This Is What Whales Are Betting On DexCom | Nasdaq Coupon?

How did Dexcom perform in 3 months?

Revenue Growth: Over the 3 months period, DexCom showcased positive performance, achieving a revenue growth rate of 24.21% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. ...

Is Dexcom a good company?

With an impressive net margin of 15.9%, the company showcases strong profitability and effective cost control. Return on Equity (ROE): DexCom's ROE excels beyond industry benchmarks, reaching 6.78%. This signifies robust financial management and efficient use of shareholder equity capital. ...

Is Dexcom a competitive market?

Even with regard to competition, DexCom remains upbeat. Bear in mind that this is a competitive market with major players like Medtronic plc ( MDT) and Abbott Laboratories ( ABT ), both of which are mega-corporations in healthcare capable of spending millions on R&D in specific areas. ...

How do analysts evaluate Dexcom (Dexcom)?

This information provides a snapshot of how analysts perceive the current state of the company. Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market. ...

Do weight loss drugs compete with Dexcom?

Additionally, and in light of GLP-1s, it seems that my expectations have been confirmed. Weight loss drugs do not necessarily compete with DexCom. They may even increase demand for DexCom's products! According to the company, it is seeing increased interest in the integration of continuous glucose monitoring with new drug therapies. ...

Is Dexcom a good stock to buy in 2025?

With a focus on reimbursement, international market expansion, and confident competition strategies, DexCom navigates challenges better than most may have expected. While valuation poses a challenge, with a blended P/E ratio of 83x, the company's growth trajectory suggests the potential for elevated double-digit annual returns through 2025. ...